Liquidia Corporation

NASDAQ:LQDA

Biotechnology

Healthcare
$56.40 +0.34%

+$0.23 today

Market cap
$5.08B
Beta
0.59
P/E (TTM)
271.8
EPS (TTM)
$0.25
52W Low $11.85High $73.22

Volume 1.22M

Average 1.50M

LQDA Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

Liquidia CorporationNASDAQ: LQDA

Free Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Free cash flow turns positive

Q2 FY2026 free cash flow was $69.01M, compared with -$40.54M a year earlier. Trailing-twelve-month free cash flow was $60.51M. Over 3 fiscal years it compounded at +11.1% a year.

Context

  • Free cash flow amounted to 25.3% of revenue in FY2025, down 677.6 pp from a year earlier.
  • Free cash flow grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly free cash flow holds near $69.01M or moves back toward the trailing-twelve-month quarterly average of $15.13M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$69.01M+272.4% QoQ
Last fiscal yearDec 2025
-$40.02M-59.3% YoY
LTMJun 2026
$60.51M+148.8% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+270.2%——
1 year-59.3%——
3-year CAGR+11.1%——
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
(40.02M) USD
Year-over-year change
+59.3%

Free Cash Flow vs competitors

How LQDA compares with its peers on the latest reported figures

  • Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +148.8% is the highest of 4, against a peer median of -3.6%.
  • Free cash flow amounts to 13.4% of revenue for LQDA, versus a peer median of 73.6%.
LQDA Competitors
Free Cash Flow for LQDA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
UTHRUnited Therapeutics CorporationLTM Jun 2026$1.09B USD+2.1%+16.2%34.6%
INSMInsmed IncorporatedLTM Jun 2026$837.67M USD-3.6%+33.1%73.6%
VCREVicore Pharma Holding ABLTM Jun 2026SEK 225.86M SEK-31.6%+7.4%16982.6%
LQDALiquidia CorporationLTM Jun 2026$60.51M USD+148.8%+11.1%13.4%
AVLNAvalyn Pharma Inc. Common Stock—— ———
Peer median (excluding LQDA) —-3.6%+16.2%73.6%

Competitors are the stored peer set for LQDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(34.58M)(41.02M)(78.5M)(130.39M)(68.92M)
Depreciation & Amortization5.61M3.65M2.18M2.2M1.53M
Deferred Income Tax00000
Stock-Based Compensation6.75M9.3M10.09M18.81M29.47M
Change in Working Capital(12.38M)(2.16M)5.87M(4.79M)(24.18M)
Accounts Receivables(2.99M)(2.03M)956K1.34M(51.37M)
Inventory000(241K)(22.99M)
Accounts Payables(7.56M)814K(1.15M)2.33M(2.59M)
Other Working Capital(1.83M)(945K)6.07M(8.22M)52.77M
Other Non-Cash Items566K1.64M18.8M20.76M26.42M
Operating Cash Flow(34.04M)(28.59M)(41.56M)(93.42M)(35.69M)
Capital Expenditures(107K)(592K)(1.29M)(4.95M)(4.34M)
Acquisitions (Net)05K000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00(10M)(3.49M)(2M)
Investing Cash Flow(107K)(587K)(11.29M)(8.44M)(6.34M)
Debt Repayment(420K)8.96M19.37M52.5M53.82M
Common Stock Issued21.71M54.46M24.24M138.55M4.82M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities5.03M1.55M(363K)3.61M1.08M
Financing Cash Flow26.32M64.96M43.25M194.66M59.73M
Effect of Forex Changes0000(3.5M)
Net Change in Cash(7.82M)35.79M(9.6M)92.8M14.2M
Free Cash Flow(34.14M)(29.18M)(42.85M)(98.37M)(40.02M)

Liquidia Corporation

NASDAQ:LQDA

Intrinsic Alpha fair value

Locked

Current Price

$56.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.